|
Metastatic melanoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Birth Weight
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors.
|
31043758 |
2019 |
|
Post-Traumatic Stress Disorder
|
0.030 |
Biomarker
|
disease |
BEFREE |
After controlling for MST and probable posttraumatic stress disorder (PTSD) at Time 1, IPV-related TBI with persistent symptoms at Time 1 remained significantly associated with worse Time 2 symptoms of insomnia, depression, and physical health (sr<sup>2</sup> range: 0.12-0.25).
|
31203176 |
2019 |
|
Post-Traumatic Stress Disorder
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our results provide initial support for the use of CPT in female veterans with MST-related PTSD and comorbid BPD.
|
28767012 |
2018 |
|
Post-Traumatic Stress Disorder
|
0.030 |
Biomarker
|
disease |
BEFREE |
Combat cohorts saw a greater reduction in PTSD symptoms over time relative to MST cohorts.
|
30053860 |
2018 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Since the RA/SARAH affinity is relatively low, whereas that of the SARAH heterodimer is in the nM range, we suggest that RASSF5 exerts its tumor suppressor action through competition with other Ras effectors for Ras effector binding site, as well as coincidentally its recruitment to the membrane to help MST activation.
|
28197608 |
2017 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In conclusion, despite the high therapeutic potential of TIs such as MST-312, the molecular outcomes of long-term exposure of tumors on these drugs have to be evaluated when considering their clinical application, especially for breast cancer treatment.
|
28520570 |
2017 |
|
Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Moreover, t-SNE and MST-kNN clustering approaches based on 10,000 probes, associated with luminal tumour initiation and/or development, revealed the close connections between luminal A and B tumours, with no evidence of a clear boundary between them.
|
27341628 |
2016 |
|
MYELOPROLIFERATIVE SYNDROME, TRANSIENT
|
0.020 |
Biomarker
|
disease |
BEFREE |
3-MST-attenuated ECs subjected to shRNA or pharmacological inhibition of 3-MST significantly reduced EC proliferation, migration, and tube-like network formation.
|
30644090 |
2020 |
|
Malignant tumor of colon
|
0.020 |
Biomarker
|
disease |
BEFREE |
Increased expression of iNOS, nNOS, HO-1, CBS and 3-MST was detected in colon cancer.
|
29074106 |
2018 |
|
Pancreatic carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
However, it remains unclear whether other MST-MOB complexes are also involved in regulating Hippo-YAP signaling and have potential roles in PC.
|
30072378 |
2018 |
|
Malignant neoplasm of pancreas
|
0.020 |
Biomarker
|
disease |
BEFREE |
However, it remains unclear whether other MST-MOB complexes are also involved in regulating Hippo-YAP signaling and have potential roles in PC.
|
30072378 |
2018 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
These data suggest that loss of MST/Hippo signaling acts with <i>Pax3:Foxo1</i> expression and <i>Cdkn2a</i> loss to promote tumorigenesis.
|
30093562 |
2018 |
|
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Increased expression of iNOS, nNOS, HO-1, CBS and 3-MST was detected in colon cancer.
|
29074106 |
2018 |
|
Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
MicroRNA-155 targets MAP3K10 and regulates osteosarcoma cell growth.
|
28214207 |
2017 |
|
Osteosarcoma of bone
|
0.020 |
Biomarker
|
disease |
BEFREE |
MicroRNA-155 targets MAP3K10 and regulates osteosarcoma cell growth.
|
28214207 |
2017 |
|
Childhood Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
MicroRNA-155 targets MAP3K10 and regulates osteosarcoma cell growth.
|
28214207 |
2017 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Inhibition of telomere activity by MST-312 further increased cancer cell radiosensitivity to carbon-ion radiation. hTERT suppression caused by either carbon-ion irradiation or MST-312 impaired mitochondrial function, as indicated by decreased membrane potential, mtDNA copy number, mitochondrial mass, total ATP levels and elevated reactive oxygen species (ROS).
|
27221886 |
2016 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Inhibition of telomere activity by MST-312 further increased cancer cell radiosensitivity to carbon-ion radiation. hTERT suppression caused by either carbon-ion irradiation or MST-312 impaired mitochondrial function, as indicated by decreased membrane potential, mtDNA copy number, mitochondrial mass, total ATP levels and elevated reactive oxygen species (ROS).
|
27221886 |
2016 |
|
MYELOPROLIFERATIVE SYNDROME, TRANSIENT
|
0.020 |
Biomarker
|
disease |
BEFREE |
FOXM1 played an important role in MST and prompted a poor prognosis for MST patients.
|
26451068 |
2015 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MST-312 decreased telomerase activity and induced telomere dysfunction and growth arrest in breast cancer cells with more profound effects in MDA-MB-231 than in MCF-7 cells.
|
26022559 |
2014 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Our work demonstrates potential importance for the establishment of antitelomerase cancer therapy using MST-312 along with PARP-1 inhibition in breast cancer therapy.
|
26022559 |
2014 |
|
Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In contrast, MST-312 did not induce DSBs in telomerase negative osteosarcoma cells (U2OS).
|
25307264 |
2014 |
|
Osteosarcoma of bone
|
0.020 |
Biomarker
|
disease |
BEFREE |
In contrast, MST-312 did not induce DSBs in telomerase negative osteosarcoma cells (U2OS).
|
25307264 |
2014 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MST-312 decreased telomerase activity and induced telomere dysfunction and growth arrest in breast cancer cells with more profound effects in MDA-MB-231 than in MCF-7 cells.
|
26022559 |
2014 |